超声结构异常胎儿的产前染色体微阵列检测:一项超过1000例连续病例的前瞻性队列研究
NT增厚组致病性CNV为5.9%(22例)、VUS为0.5%(2例);中孕期异常组分别为7.3%(55例)和0.8%(6例)。NT小于4.0 mm的胎儿未发现致病性CNV。
要点
- NT增厚组致病性CNV检出率为5.9%(22例),中孕期结构异常组为7.3%(55例)。
- NT小于4.0 mm的胎儿未检出致病性CNV。
- 多系统和心脏异常致病性CNV检出率最高,其中22q11.2微缺失占40%(12/30)。
核心结论
- 产前aCGH是评估NT显著增厚或结构异常胎儿的有用诊断工具。
- 随着时间和经验积累,致病性CNV检出率增加、VUS减少,支持产前应用分辨率日益提高的aCGH平台。
研究设计与样本
- 前瞻性队列研究,于2013年3月至2017年6月纳入超声发现NT增厚或结构异常且常见非整倍体检测阴性的胎儿。
- aCGH采用8重寡核苷酸平台,全基因组骨架分辨率大于200 kb,结果判读参照美国医学遗传学与基因组学学会指南。
主要发现
- NT增厚组致病性CNV检出率为5.9%(n=22),VUS为0.5%(n=2)。
- 中孕期结构异常组致病性CNV检出率为7.3%(n=55),VUS为0.8%(n=6)。
- NT小于4.0 mm的胎儿中未发现致病性CNV。
- 多系统和心脏异常的致病性CNV检出率最高,22q11.2微缺失占40%(12/30)。
关键数值与推荐
- NT增厚组致病性CNV 5.9%(n=22)、VUS 0.5%(n=2)。
- 中孕期结构异常组致病性CNV 7.3%(n=55)、VUS 0.8%(n=6)。
- 多系统和心脏异常中22q11.2微缺失占40%(12/30)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluate the diagnostic yield of prenatal submicroscopic chromosome anomalies using prenatal array comparative genomic hybridisation (aCGH). METHOD: Prospective cohort study conducted between March 2013 and June 2017 including fetuses where an elevated nuchal translucency (NT) or structural anomaly was identified on ultrasound and common aneuploidy testing was negative. aCGH was performed using an 8-plex oligonucleotide platform with a genome wide backbone resolution of greater than 200 kb and interpretation in line with American College of Medical Genetics guidance. RESULTS: One thousand one hundred twenty-nine fetuses were included; 371 fetuses with an increased NT (32.9%) and 758 with a structural anomaly (67.1%). The rate of pathogenic copy number variants (CNVs) and variant of uncertain significance (VUS) was 5.9% (n = 22) and 0.5% (n = 2) in the elevated NT group and 7.3% (n = 55) and 0.8% (n = 6) in the mid-trimester anomaly group. No pathogenic CNVs were identified in fetuses with an NT less than 4.0 mm. Multisystem and cardiac anomalies had the greatest yield of pathogenic CNV with a 22q11.2 microdeletion present in 40% (12/30). CONCLUSION: Prenatal aCGH is a useful diagnostic tool in the investigation of fetuses with a significantly elevated NT or structural anomaly. With time and experience, rates of pathogenic CNVs have increased, and VUS have reduced, supporting the prenatal application of increasingly high resolution aCGH platforms.
引用
- Chong HP, Hamilton S, Mone F, et al. Prenatal chromosomal microarray testing of fetuses with ultrasound structural anomalies: A prospective cohort study of over 1000 consecutive cases. Prenat Diagn. 2019. PMID: 31393021. doi:10.1002/pd.5545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。